BioSpace News Archive

TTP Plc today announced the launch of the award-winning Cyto-Mine Single Cell Analysis System. Recently awarded a Frost and Sullivan award for Product Innovation.

The company provided a corporate overview and business outlook for the remainder of 2017.

Syndax today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharma for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the MLL protein.

BrainStorm announced financial results for the third quarter ending September 30, 2017.

Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of a Phase 1 clinical study of a subtype selective NMDA receptor NAM for the treatment of treatment-resistant depression.

Syndax today announced that it has agreed to sell 2,021,018 shares of its common stock to BVF in a registered direct offering.

Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced today the release of a current literature review on the “Clinical and Biomechanical Advantages of Interspinous Process Fixation.”

Can-Fite BioPharma Ltd today announced the Korean Intellectual Property Office has issued patent No. 10-1741281 titled, “Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-MECA/CF-101) For Treatment of Psoriasis” for the Company’s lead drug candidate Piclidenoson (CF101) in its psoriasis indication.

Verastem today announced payment of a $6 million milestone to Infinity Pharma, representing the first milestone under the duvelisib license agreement between Verastem and Infinity.

Ignyta, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for entrectinib in the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapy.